Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)

https://www.sygnis.de

SYGNIS AG develops and commercialises value-added, easy-to-use, reliable products based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With the acquisitions of Expedeon Holdings, Ltd. in 2016 and both C.B.S. Scientific Company, Inc. and Innova Biosciences Ltd. in 2017, SYGNIS significantly expanded its product line and now covers the entire molecular biology workflow, including genomics, proteomics and tools as well as cutting-edge bioconjugation technologies and services. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. The SYGNIS Group has offices in Germany, Spain and the UK; production sites in the UK and the U.S. and sales offices in Asia. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). *

	Start	2013-10-28 renamed before
	Group	2invest (Group)
	Predecessor	Sygnis Pharma AG
	Industry	Qualiphi® DNA polymerase
	Industry 2	Next Generation Sequencing (NGS) technology
	Person	de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)

	Region	Heidelberg
	Country	Germany
	Street	515 Im Neuenheimer Feld
	City	69120 Heidelberg
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2014-11-11)
	Currency	EUR
	Annual sales	1,789,000 (revenues (2016) 2016-12-31)
	Profit	-4,388,000 (2015-12-31)
	Cash	3,795,000 (2016-12-31)

		* Document for »About Section«: Sygnis AG. (10/18/17). "Press Release: Sygnis AG Announces Completion of Relocation of Its Innova Biosciences Unit to Allow for Expansion". Madrid & Heidelberg.

		Record changed: 2023-12-30